Marcelo Pitombeira de Lacerda

Statistics

Publications

Citations

246

H-Index

Active since

2019

Affiliations

Universidade da Região de Joinville(Current)

University Hospital Ostrava

Medical University of Lodz

University of Ostrava

First Affiliated Hospital of Soochow University

Marcelo Pitombeira de Lacerda is an author at Universidade da Região de Joinville specializing in neoplastic lymphoid differentiation, b cell regulation, and cell signaling.

ORCID

Publications per year

2019–2025

Publications

Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma

Vânia Hungria, Paweł Robak, Marek Hus et al. · New England Journal of Medicine · 2024 · 166 citations

Medicine, Pharmacology, Pharmacotherapy +13

Genetics, Cytogenetic Testing And Conventional Karyotype

Ekin Ozkan, Marcelo Pitombeira de Lacerda · 2021 · 20 citations

Life Sciences, Genetics, Molecular Genetics +17

Deregulation of Ikaros expression in B-1 cells: New insights in the malignant transformation to chronic lymphocytic leukemia

Vivian Cristina de Oliveira, Marcelo Pitombeira de Lacerda, Bárbara Bomfim Muniz Moraes et al. · Journal of Leukocyte Biology · 2019 · 16 citations

Life Sciences, Cell Biology, Molecular Biology +15

Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial

Vânia Hungria, Paweł Robak, Marek Hus et al. · The Lancet Oncology · 2025 · 16 citations

Medicine, Pharmacology, Pharmacotherapy +11

Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial

Vânia Hungria, Paweł Robak, Marek Hus et al. · Blood · 2024 · 14 citations

Medicine, Pharmacology, Pharmacotherapy +17

1–5 of 6